Trial reportAddictive behaviors2025
Characteristics associated with medication adherence in a randomized clinical trial of multiple pharmacotherapy adaptations based on treatment response in black adults who smoke.
Trial report in Addictive behaviors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionPharmacotherapy is a key component of evidence-based smoking cessation treatment and a major predictor of success in quitting. However, most people attempting to quit in clinical trials fail to fully adhere to their pharmacological treatments. AIMS AND
methodsTo assess factors associated with adherence to smoking cessation pharmacotherapies among Black adults participating in a clinical trial and to understand reasons for non-adherence to treatment. Data came from 333 participants enrolled in a randomized clinical trial of adapted therapy (ADT) or enhanced usual care (UC) for smoking cessation. Medication adherence was defined as taking at least 80 % of the prescribed medication for the entire treatment. Characteristics associated with 18-week adherence included demographic, psychosocial, smoking characteristics, substance use, medication experience, early treatment response, and adverse events. A best-subsets regression analyses were performed with all characteristics, and descriptive statistics were used to summarize the reasons for non-adherence to medication.
resultsOne hundred seventy-seven participants were compliant with their medication. Participants randomized to the ADT (OR = 2.40, 95 % CI = 1.52-3.81, p < 0.001) and with more positive medication experience (OR = 1.28, 95 % CI = 1.14-1.45, p < 0.001) were more likely to be adherent to study medications. The most common reason for non-adherence was "forgetting or losing the medication" (49.1 %).
conclusionsOver half of our sample were adherent to their pharmacotherapy, and those randomized to adaptive therapy, coupled with a positive experience with their medication, exhibited better overall compliance with their long-term pharmacotherapy. Reasons for not taking medications were similar to the existing literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.